FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007264925> ?p ?o ?g. }

• W3007264925 endingPage "1277" @default.
• W3007264925 startingPage "1268" @default.
• W3007264925 abstract "Urothelial carcinomas of the upper urinary tract (UTUCs) are rare, with poorer stage-for-stage prognosis than urothelial carcinomas of the urinary bladder. No international consensus exists on the benefit of adjuvant chemotherapy for patients with UTUCs after nephroureterectomy with curative intent. The POUT (Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer) trial aimed to assess the efficacy of systemic platinum-based chemotherapy in patients with UTUCs.We did a phase 3, open-label, randomised controlled trial at 71 hospitals in the UK. We recruited patients with UTUC after nephroureterectomy staged as either pT2-T4 pN0-N3 M0 or pTany N1-3 M0. We randomly allocated participants centrally (1:1) to either surveillance or four 21-day cycles of chemotherapy, using a minimisation algorithm with a random element. Chemotherapy was either cisplatin (70 mg/m2) or carboplatin (area under the curve [AUC]4·5/AUC5, for glomerular filtration rate <50 mL/min only) administered intravenously on day 1 and gemcitabine (1000 mg/m2) administered intravenously on days 1 and 8; chemotherapy was initiated within 90 days of surgery. Follow-up included standard cystoscopic, radiological, and clinical assessments. The primary endpoint was disease-free survival analysed by intention to treat with a Peto-Haybittle stopping rule for (in)efficacy. The trial is registered with ClinicalTrials.gov, NCT01993979. A preplanned interim analysis met the efficacy criterion for early closure after recruitment of 261 participants.Between June 19, 2012, and Nov 8, 2017, we enrolled 261 participants from 57 of 71 open study sites. 132 patients were assigned chemotherapy and 129 surveillance. One participant allocated chemotherapy withdrew consent for data use after randomisation and was excluded from analyses. Adjuvant chemotherapy significantly improved disease-free survival (hazard ratio 0·45, 95% CI 0·30-0·68; p=0·0001) at a median follow-up of 30·3 months (IQR 18·0-47·5). 3-year event-free estimates were 71% (95% CI 61-78) and 46% (36-56) for chemotherapy and surveillance, respectively. 55 (44%) of 126 participants who started chemotherapy had acute grade 3 or worse treatment-emergent adverse events, which accorded with frequently reported events for the chemotherapy regimen. Five (4%) of 129 patients managed by surveillance had acute grade 3 or worse emergent adverse events. No treatment-related deaths were reported.Gemcitabine-platinum combination chemotherapy initiated within 90 days after nephroureterectomy significantly improved disease-free survival in patients with locally advanced UTUC. Adjuvant platinum-based chemotherapy should be considered a new standard of care after nephroureterectomy for this patient population.Cancer Research UK." @default.
• W3007264925 created "2020-03-06" @default.
• W3007264925 creator A5002802780 @default.
• W3007264925 creator A5003521413 @default.
• W3007264925 creator A5006781362 @default.
• W3007264925 creator A5014098880 @default.
• W3007264925 creator A5015672227 @default.
• W3007264925 creator A5016227054 @default.
• W3007264925 creator A5017488456 @default.
• W3007264925 creator A5019263397 @default.
• W3007264925 creator A5022702970 @default.
• W3007264925 creator A5024736921 @default.
• W3007264925 creator A5031522630 @default.
• W3007264925 creator A5032231578 @default.
• W3007264925 creator A5048796030 @default.
• W3007264925 creator A5049636639 @default.
• W3007264925 creator A5054035549 @default.
• W3007264925 creator A5055511152 @default.
• W3007264925 creator A5059792318 @default.
• W3007264925 creator A5063186397 @default.
• W3007264925 creator A5064617740 @default.
• W3007264925 creator A5072911394 @default.
• W3007264925 creator A5076600357 @default.
• W3007264925 creator A5079126831 @default.
• W3007264925 creator A5079820994 @default.
• W3007264925 creator A5080026724 @default.
• W3007264925 date "2020-04-01" @default.
• W3007264925 modified "2023-10-14" @default.
• W3007264925 title "Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial" @default.
• W3007264925 cites W1524063860 @default.
• W3007264925 cites W1527366898 @default.
• W3007264925 cites W1893740135 @default.
• W3007264925 cites W2022188526 @default.
• W3007264925 cites W2048519490 @default.
• W3007264925 cites W2056309356 @default.
• W3007264925 cites W2091949712 @default.
• W3007264925 cites W2103561213 @default.
• W3007264925 cites W2118581974 @default.
• W3007264925 cites W2120955645 @default.
• W3007264925 cites W2136032744 @default.
• W3007264925 cites W2137616140 @default.
• W3007264925 cites W2148562299 @default.
• W3007264925 cites W2171883057 @default.
• W3007264925 cites W2414442728 @default.
• W3007264925 cites W2550856922 @default.
• W3007264925 cites W2559804019 @default.
• W3007264925 cites W2588916311 @default.
• W3007264925 cites W2623134322 @default.
• W3007264925 cites W2762965865 @default.
• W3007264925 cites W2770275799 @default.
• W3007264925 cites W2772689211 @default.
• W3007264925 cites W2777192533 @default.
• W3007264925 cites W2803771593 @default.
• W3007264925 cites W2946128073 @default.
• W3007264925 cites W2954656275 @default.
• W3007264925 cites W4249552371 @default.
• W3007264925 doi "https://doi.org/10.1016/s0140-6736(20)30415-3" @default.
• W3007264925 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7181180" @default.
• W3007264925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32145825" @default.
• W3007264925 hasPublicationYear "2020" @default.
• W3007264925 type Work @default.
• W3007264925 sameAs 3007264925 @default.
• W3007264925 citedByCount "263" @default.
• W3007264925 countsByYear W30072649252020 @default.
• W3007264925 countsByYear W30072649252021 @default.
• W3007264925 countsByYear W30072649252022 @default.
• W3007264925 countsByYear W30072649252023 @default.
• W3007264925 crossrefType "journal-article" @default.
• W3007264925 hasAuthorship W3007264925A5002802780 @default.
• W3007264925 hasAuthorship W3007264925A5003521413 @default.
• W3007264925 hasAuthorship W3007264925A5006781362 @default.
• W3007264925 hasAuthorship W3007264925A5014098880 @default.
• W3007264925 hasAuthorship W3007264925A5015672227 @default.
• W3007264925 hasAuthorship W3007264925A5016227054 @default.
• W3007264925 hasAuthorship W3007264925A5017488456 @default.
• W3007264925 hasAuthorship W3007264925A5019263397 @default.
• W3007264925 hasAuthorship W3007264925A5022702970 @default.
• W3007264925 hasAuthorship W3007264925A5024736921 @default.
• W3007264925 hasAuthorship W3007264925A5031522630 @default.
• W3007264925 hasAuthorship W3007264925A5032231578 @default.
• W3007264925 hasAuthorship W3007264925A5048796030 @default.
• W3007264925 hasAuthorship W3007264925A5049636639 @default.
• W3007264925 hasAuthorship W3007264925A5054035549 @default.
• W3007264925 hasAuthorship W3007264925A5055511152 @default.
• W3007264925 hasAuthorship W3007264925A5059792318 @default.
• W3007264925 hasAuthorship W3007264925A5063186397 @default.
• W3007264925 hasAuthorship W3007264925A5064617740 @default.
• W3007264925 hasAuthorship W3007264925A5072911394 @default.
• W3007264925 hasAuthorship W3007264925A5076600357 @default.
• W3007264925 hasAuthorship W3007264925A5079126831 @default.
• W3007264925 hasAuthorship W3007264925A5079820994 @default.
• W3007264925 hasAuthorship W3007264925A5080026724 @default.
• W3007264925 hasBestOaLocation W30072649251 @default.
• W3007264925 hasConcept C121608353 @default.
• W3007264925 hasConcept C126322002 @default.
• W3007264925 hasConcept C126894567 @default.
• W3007264925 hasConcept C141071460 @default.
• W3007264925 hasConcept C143998085 @default.

• next